OverviewSuggest Edit

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, and clinical development. 
TypePublic
Founded2009
HQWestminster, US
Websitearcabio.com

Latest Updates

Employees (est.) (Dec 2018)15(-25%)
Share Price (May 2019)$7.2 (-9%)

ARCA biopharma Office Locations

ARCA biopharma has offices in Westminster and Aurora
Westminster, US (HQ)
11080 Circle Point Rd #140
Aurora, US
12635 E Montview Blvd
Westminster, US
11080 Circle Point Rd #140
Show all (3)

ARCA biopharma Financials and Metrics

ARCA biopharma Revenue

USD

Net income (Q1, 2019)

(1.7m)

EBIT (Q1, 2019)

(1.8m)

Market capitalization (22-May-2019)

17.8m

Closing stock price (22-May-2019)

7.2

Cash (31-Mar-2019)

8.0m
ARCA biopharma's current market capitalization is $17.8 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

4.3m4.6m3.9m

R&D expense

12.3m14.1m4.2m

Operating expense total

16.6m18.7m8.1m

EBIT

(16.6m)(18.7m)(8.1m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

General and administrative expense

1.0m950.0k972.0k1.1m1.1m1.0m992.0k1.1m1.1m987.0k1.1m1.0m922.0k1.1m

R&D expense

1.4m1.3m1.7m1.7m2.6m2.9m3.7m3.2m4.5m3.5m1.7m1.2m740.0k662.0k

Operating expense total

2.4m2.3m2.7m2.8m3.7m3.9m4.7m4.4m5.6m4.5m2.8m2.2m1.7m1.8m

EBIT

(2.4m)(2.3m)(2.7m)(2.8m)(3.7m)(3.9m)(4.7m)(4.4m)(5.6m)(4.5m)(2.8m)(2.2m)(1.7m)(1.8m)
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

16.8m38.8m7.4m8.7m6.6m

Current Assets

16.9m38.9m21.4m12.3m6.8m

PP&E

29.0k28.0k66.0k42.0k24.0k

Total Assets

17.1m39.6m24.6m12.4m6.8m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(6.9m)(11.4m)(16.4m)(18.5m)(7.9m)

Depreciation and Amortization

26.0k19.0k24.0k27.0k22.0k

Accounts Payable

532.0k(431.0k)841.0k(583.0k)(392.0k)

Cash From Operating Activities

(5.3m)(10.5m)(15.0m)(17.5m)(8.2m)
Quarterly
USDY, 2019

Financial Leverage

1.2 x
Show all financial metrics

ARCA biopharma News and Updates

Thinking about buying stock in Arca Biopharma, Cronos Group, Nio Inc., Precipio, or Square?

NEW YORK, May 2, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABIO, CRON, NIO, PRPO, and SQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial Evaluating Gencaro as Potentially the First Genetically-Targeted Treatment for Atrial Fibrillation Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial Evaluating Gencaro as…

ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

Initiation of Pivotal Phase 3 PRECISION-AF Clinical Trial Anticipated in Fourth Quarter Initiation of Pivotal Phase 3 PRECISION-AF Clinical Trial Anticipated in Fourth Quarter

Thinking about buying stock in ARCA biopharma, Clearside Biomedical, Kandi Technologies, Nike or Tahoe Resources?

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABIO, CLSD, KNDI, NKE, and TAHO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...

ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Nov. 14, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 3…

ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Plan Completed; Single Additional Phase 3 Trial Planned to Support NDA Submission End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Plan Completed; Single Additional Phase 3 Trial Pl…

ARCA biopharma Frequently Asked Questions

  • When was ARCA biopharma founded?

    ARCA biopharma was founded in 2009.

  • How many employees does ARCA biopharma have?

    ARCA biopharma has 15 employees.

  • Who are ARCA biopharma competitors?

    Competitors of ARCA biopharma include Intellia Therapeutics, Ultragenyx Pharmaceutical and Vical.

  • Where is ARCA biopharma headquarters?

    ARCA biopharma headquarters is located at 11080 Circle Point Rd #140, Westminster.

  • Where are ARCA biopharma offices?

    ARCA biopharma has offices in Westminster and Aurora.

  • How many offices does ARCA biopharma have?

    ARCA biopharma has 3 offices.